Novo Nordisk的首席执行官Lars Fruergaard Jørgensen在公司股价下跌50%的情况下辞职。 Novo Nordisk's CEO, Lars Fruergaard Jørgensen, resigns amid a 50% drop in the company’s share price.

制药公司Novo Nordisk首席执行官Lars Fruergaard Jørgensen由于与董事会达成相互协议,在市场挑战和2024年年中以来公司股价下降50%的情况下,正在下台。 Lars Fruergaard Jørgensen, CEO of pharmaceutical company Novo Nordisk, is stepping down due to a mutual agreement with the board, amid market challenges and a 50% drop in the company's share price since mid-2024. Jørgensen将继续临时发挥其作用,以确保平稳过渡。 Jørgensen will continue in his role temporarily to ensure a smooth transition. 该公司的销售额和利润在他八年任期内几乎增加了两倍,但最近来自廉价复制药品和竞争产品的竞争影响了Wegovy的销售。 The company's sales and profits have almost tripled under his eight-year tenure, but recent competition from cheaper replica drugs and rival products have impacted Wegovy sales.